



**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of

MIYAKE, Akira, et al.

Appln. No.: 09/965,830

Filed: October 01, 2001

For: NOVEL POTASSIUM CHANNEL PROTEIN

Docket No: Q66067

Confirmation No.: 3999

Group Art Unit: 1653

Examiner: J. Seharaseyon

**REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT**

Commissioner for Patents  
Office of Initial Patent Examination  
Customer Service Center  
Washington, D.C. 20231

Sir:

We enclose a copy of the Official Filing Receipt for the above-identified application and request the following corrections:

In the title, please correct the spelling of the word "postassium" to "potassium."

In the Domestic Priority data, please revise the information listed to include that the parent application (09/600,776) is a 371 of PCT/JP99/00190, filed January 20, 1999.

Verification for the requested corrections is indicated on the original executed Declaration and Power of Attorney filed October 1, 2001, a copy of which is enclosed herewith.

Respectfully submitted,

Drew Hisson  
Registration No. 44,765

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE



23373


PATENT TRADEMARK OFFICE

RECEIVED  
APR 15 2003  
TECH CENTER 1600/2900

Date: April 4, 2003



## UNITED STATES PATENT AND TRADEMARK OFFICE



COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
✓09/965,830	✓10/01/2001	1653	✓740	✓Q66067		✓15	3

CONFIRMATION NO. 3999

## FILING RECEIPT



\*OC000000007295788\*

SUGHRUE, MIOIN, ZINN,  
MACPEAK & SEAS, PLLC  
2100 Pennsylvania Avenue, N.W.  
Washington, DC 20037-3213

Date Mailed: 01/11/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

✓Akira Miyake, Ibaraki, JAPAN;  
✓Shinobu Mochizuki, Ibaraki, JAPAN;  
✓Hiromichi Yokoi, Ibaraki, JAPAN;

RECEIVED

APR 15 2003

## Assignment For Published Patent Application

✓YAMANOUCHI PHARMACEUTICAL CO., LTD.;

TECH CENTER 1600/2900

## Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CON OF 09/600,776 07/21/2000 PAT 6,326,168, which is a 371 of  
PCT/JP99/00190 01/20/1999

## Foreign Applications

✓JAPAN P. HEI. 10-11434 01/23/1998  
✓JAPAN P. HEI. 10-346198 12/04/1998


If Required, Foreign Filing License Granted 01/10/2002

Projected Publication Date: 04/18/2002

Non-Publication Request: No

Early Publication Request: No

Title



Preliminary Class

435

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



Commissioner for Patents  
Washington, DC 20231  
www.uspto.gov



Bib Data Sheet

CONFIRMATION NO. 3999

<b>SERIAL NUMBER</b> 09/965,830	<b>FILING DATE</b> 10/01/2001 <b>RULE</b>	<b>CLASS</b> 435	<b>GROUP ART UNIT</b> 1647	<b>ATTORNEY DOCKET NO.</b> Q66067	
<b>APPLICANTS</b> Akira Miyake, Ibaraki, JAPAN; Shinobu Mochizuki, Ibaraki, JAPAN; Hiromichi Yokoi, Ibaraki, JAPAN;					
<b>** CONTINUING DATA *****</b> This application is a CON of 09/600,776 07/21/2000 PAT 6,326,168 which is a 371 of PCT/JP99/00190 01/20/1999					
<b>** FOREIGN APPLICATIONS *****</b> JAPAN P. HEI. 10-11434 01/23/1998 JAPAN P. HEI. 10-346198 12/04/1998					
<b>IF REQUIRED, FOREIGN FILING LICENSE GRANTED</b> <b>** 01/10/2002</b>					
Foreign Priority claimed <input type="checkbox"/> yes <input type="checkbox"/> no 35 USC 119 (a-d) conditions <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after met Allowance Verified and Acknowledged <u>Examiner's Signature</u> Initials		<b>STATE OR COUNTRY</b> JAPAN	<b>SHEETS DRAWING</b> 0	<b>TOTAL CLAIMS</b> 15	<b>INDEPENDENT CLAIMS</b> 3
<b>ADDRESS</b> SUGHRUE, MIOIN, ZINN, MACPEAK & SEAS, PLLC 2100 Pennsylvania Avenue, N.W. Washington, DC 20037-3213					
<b>TITLE</b> Novel potassium channel protein					
<b>FILING FEE RECEIVED</b> 740	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:		<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees ( Filing ) <input type="checkbox"/> 1.17 Fees ( Processing Ext. of time ) <input type="checkbox"/> 1.18 Fees ( Issue ) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit		

RECEIVED  
APR 15 2003  
TECH CENTER 1600/2900